The latest announcement is out from India Globalization Capital Inc (IGC).
IGC Pharma Inc. announced promising interim results from a Phase 2 trial of IGC-AD1, showing a significant reduction in Alzheimer’s-related agitation. The data revealed both clinical and statistical improvements in patients’ agitation levels as early as week two, with continued benefits at the six-week mark. This breakthrough suggests IGC-AD1 could be a powerful new treatment option for managing symptoms associated with Alzheimer’s disease.
Learn more about IGC stock on TipRanks’ Stock Analysis page.
